8.5 USD
+0.01 (+0.12%)
Last: Sep 25, 2023, 08:00 PM
LMNL gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 525 industry peers in the Biotechnology industry. LMNL may be in some trouble as it scores bad on both profitability and health. LMNL does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
- LMNL had positive earnings in the past year.
- LMNL had a negative operating cash flow in the past year.
1.2 Ratios
- With an excellent Return On Assets value of 1.46%, LMNL belongs to the best of the industry, outperforming 93.73% of the companies in the same industry.
- The Return On Equity of LMNL (2.16%) is better than 93.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.46% | ||
| ROE | 2.16% | ||
| ROIC | N/A |
ROA(3y)-29.63%
ROA(5y)-80.67%
ROE(3y)-159.64%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- With an excellent Profit Margin value of 94.11%, LMNL belongs to the best of the industry, outperforming 99.67% of the companies in the same industry.
- LMNL does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 94.11% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- LMNL does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for LMNL remains at a similar level compared to 1 year ago.
- The debt/assets ratio for LMNL has been reduced compared to a year ago.
2.2 Solvency
- LMNL has an Altman-Z score of -45.25. This is a bad value and indicates that LMNL is not financially healthy and even has some risk of bankruptcy.
- With a Altman-Z score value of -45.25, LMNL is not doing good in the industry: 95.71% of the companies in the same industry are doing better.
- A Debt/Equity ratio of 0.02 indicates that LMNL is not too dependend on debt financing.
- The Debt to Equity ratio of LMNL (0.02) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -45.25 |
ROIC/WACCN/A
WACC7.87%
2.3 Liquidity
- LMNL has a Current Ratio of 2.78. This indicates that LMNL is financially healthy and has no problem in meeting its short term obligations.
- LMNL has a worse Current ratio (2.78) than 74.75% of its industry peers.
- A Quick Ratio of 2.78 indicates that LMNL has no problem at all paying its short term obligations.
- Looking at the Quick ratio, with a value of 2.78, LMNL is doing worse than 72.94% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.78 | ||
| Quick Ratio | 2.78 |
3. Growth
3.1 Past
- The earnings per share for LMNL have decreased strongly by -99.10% in the last year.
- The Revenue for LMNL has decreased by -12.92% in the past year. This is quite bad
- LMNL shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -59.99% yearly.
EPS 1Y (TTM)-99.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-53.93%
Revenue 1Y (TTM)-12.92%
Revenue growth 3Y-56.58%
Revenue growth 5Y-59.99%
Sales Q2Q%-28.66%
3.2 Future
- Based on estimates for the next years, LMNL will show a very negative growth in Earnings Per Share. The EPS will decrease by -230.98% on average per year.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-907.27%
EPS Next 2Y-230.98%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 77.27, which means the current valuation is very expensive for LMNL.
- Based on the Price/Earnings ratio, LMNL is valued cheaper than 93.89% of the companies in the same industry.
- LMNL's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 28.30.
- LMNL is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 77.27 | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- LMNL's earnings are expected to decrease with -230.98% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-230.98%
EPS Next 3YN/A
5. Dividend
5.1 Amount
- LMNL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
LIMINAL BIOSCIENCES INC / LMNL FAQ
What is the ChartMill fundamental rating of LIMINAL BIOSCIENCES INC (LMNL) stock?
ChartMill assigns a fundamental rating of 2 / 10 to LMNL.
What is the valuation status for LMNL stock?
ChartMill assigns a valuation rating of 1 / 10 to LIMINAL BIOSCIENCES INC (LMNL). This can be considered as Overvalued.
Can you provide the profitability details for LIMINAL BIOSCIENCES INC?
LIMINAL BIOSCIENCES INC (LMNL) has a profitability rating of 3 / 10.
Can you provide the financial health for LMNL stock?
The financial health rating of LIMINAL BIOSCIENCES INC (LMNL) is 3 / 10.
What is the earnings growth outlook for LIMINAL BIOSCIENCES INC?
The Earnings per Share (EPS) of LIMINAL BIOSCIENCES INC (LMNL) is expected to decline by -907.27% in the next year.